What is HC Wainwright’s Forecast for Genmab A/S Q3 Earnings?

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Equities researchers at HC Wainwright reduced their Q3 2026 earnings per share estimates for shares of Genmab A/S in a note issued to investors on Wednesday, October 7th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of $0.48 per share for the quarter, down from their previous forecast of $0.49. HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.21 per share. HC Wainwright also issued estimates for Genmab A/S’s Q4 2026 earnings at $0.42 EPS and FY2026 earnings at $1.45 EPS.

Several other equities analysts have also commented on the stock. Truist Financial increased their price objective on shares of Genmab A/S from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday. TD Cowen raised shares of Genmab A/S from a “hold” rating to a “buy” rating and boosted their target price for the stock from $32.00 to $43.00 in a research report on Wednesday, July 22nd. Guggenheim upped their price target on shares of Genmab A/S from $45.00 to $54.00 and gave the company a “buy” rating in a research note on Monday. Weiss Ratings raised shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, September 1st. Finally, New Street Research set a $43.00 price objective on shares of Genmab A/S in a research note on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $42.50.

Genmab A/S Price Performance

Shares of NASDAQ GMAB opened at $36.05 on Friday. Genmab A/S has a fifty-two week low of $23.62 and a fifty-two week high of $40.17. The company has a market cap of $22.50 billion, a PE ratio of 28.39, a P/E/G ratio of 1.69 and a beta of 0.81. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.44 and a current ratio of 2.46. The business has a 50-day simple moving average of $33.45 and a two-hundred day simple moving average of $29.30.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.17. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%.The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.12 billion.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Arrowstreet Capital Limited Partnership grew its stake in shares of Genmab A/S by 36.6% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock worth $153,324,000 after purchasing an additional 1,334,919 shares during the period. First Trust Advisors LP boosted its holdings in Genmab A/S by 84.3% during the first quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock worth $66,038,000 after buying an additional 1,126,069 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Genmab A/S by 26.4% in the first quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock valued at $118,442,000 after buying an additional 921,700 shares in the last quarter. SummitTX Capital L.P. purchased a new position in Genmab A/S in the first quarter valued at $2,263,000. Finally, Ishara Investments LP acquired a new position in shares of Genmab A/S in the fourth quarter worth about $2,156,000. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including its DuoBody and HexaBody platforms, to create therapies designed to engage the immune system, target disease-related proteins and improve treatment outcomes.

Genmab’s portfolio includes products developed through partnerships as well as internally discovered candidates.